Understanding how T cells become exhausted in cancer
Uncovering the metabolic underpinnings of T cell exhaustion
This study is looking at why T cells, which help fight cancer, sometimes stop working well and how things like stress on their energy systems might be involved, with the hope that using antioxidants could help them work better again, ultimately leading to better treatments for cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10891495 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind T cell exhaustion, a condition where T cells lose their ability to fight cancer effectively. The team will explore how metabolic stress and mitochondrial dysfunction contribute to this exhaustion and how antioxidants might help restore T cell function. By studying the effects of reactive oxygen species on T cell signaling and metabolism, the researchers aim to identify potential therapeutic strategies to reinvigorate these immune cells. Patients may benefit from insights that could lead to improved cancer immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients experiencing T cell exhaustion and limited response to current immunotherapy treatments.
Not a fit: Patients with cancers that do not involve T cell exhaustion or those who are not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the effectiveness of cancer immunotherapies by restoring T cell function.
How similar studies have performed: Other research has shown promising results in understanding T cell metabolism and its impact on immune function, indicating that this approach has potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Delgoffe, Greg M. — University of Pittsburgh at Pittsburgh
- Study coordinator: Delgoffe, Greg M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.